Abstract: Provided herein are methods for detection of miRNA in a sample. In certain embodiments, the sample comprises RNA and is derived from a cell or tissue. The methods of detection employ a competitor molecule to allow for detection of an miRNA in the presence of an anti-miRNA oligonucleotide.

Abstract: A security seal for a latch and hasp closure or a similar closure including a flexible, elongated strap seal having an elongated opening therein for receiving a hasp. The seal further includes a locking post and a corresponding socket provided with one or more locking means for engaging the locking post so that the locking post cannot be removed without damaging the seal. The seal is also provided with an identification flag that is in a fixed positioned relative to the opening of the strap so that information displayed on the flag can be easily read or scanned without having to manipulate the seal.

Abstract: The present invention is a safety shield assembly having a shield and a collar for connecting the shield to a fluid handling device whereby the shield may be pivoted with respect to the collar. Preferably, the safety shield assembly may be used with a needle assembly, an intravenous infusion set a syringe, a catheter or other fluid handling devices or assemblies that contain piercing elements.

Abstract: The present invention is a method for assembling a safety shield assembly and more particularly a method for assembling a safety shield assembly with a fluid handling device. Preferably, the safety shield assembly may be assembled with a needle assembly, an intravenous infusion set a syringe, a catheter or other fluid handling devices or assemblies that contain piercing elements.

Abstract: Compositions and methods for the treatment of asthma with oligonucleotides which specifically hybridize with nucleic acids encoding B7 proteins.

Abstract: A system and method for reliable delivery of datagram protocol data unit (PDU) packets generated by a network oriented application at a first computing network element to a second computing network element across a network. The method steps include: at the first computing network element, capturing generated datagram packets destined for the second computing network element; determining a size of a payload associated with the datagram and communicating the size of the payload to the second computing element via a reliable connection-oriented transport service PDU; communicating the actual payload to the second computing element via the reliable connection-oriented transport service PDU; and, at the second computing network element, utilizing payload size and payload to reconstruct a datagram PDU including the payload for a network application at the second computing network element. By this technique, reliable datagram PDU transport over the network is ensured.

Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of hepcidin in a cell, tissue or animal or preventing, ameliorating or treating anemia. Also provided are methods for prevention, amelioration or treatment of anemia, and for increasing red blood cell count in an animal. Also provided are methods for the prevention, amelioration and/or treatment of low serum iron levels, low red blood cell count and other clinical endpoints of anemia in an animal. These methods may be achieved by administration of compounds or compositions including antisense compounds targeted to a nucleic acid that expresses hepcidin polypeptide combined with an erythropoiesis stimulating agent.

Abstract: Modified oligonucleotides having a GGG motif sequence and a sufficient number of flanking nucleotides to modulate the telomere length of a chromosome are provided. Methods of modulating telomere length of a mammalian chromosome in vitro and in vivo are also provided, as are methods for inhibiting the division of a malignant mammalian cell and for modulating the effects of cellular aging.

Abstract: Compounds, compositions and methods are provided for modulating the expression of thyroid hormone receptor interactor 3. The compositions comprise oligonucleotides, targeted to nucleic acid encoding thyroid hormone receptor interactor 3.

Abstract: Compounds, compositions and methods are provided for modulating the expression of ACE2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding ACE2. Methods of using these compounds for modulation of ACE2 expression and for diagnosis and treatment of diseases and conditions associated with expression of ACE2 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of ACE2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding ACE2. Methods of using these compounds for modulation of ACE2 expression and for diagnosis and treatment of diseases and conditions associated with expression of ACE2 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of CD40. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD40. Methods of using these compounds for modulation of CD40 expression and for treatment of diseases associated with CD40 are provided.

Abstract: Anti sense oligonucleotide compositions which specifically hybridize with nucleic acids encoding B7 proteins, and use of these compositions for inhibiting expression of B7 mRNA.

Abstract: Methods for slowing disease progression in an individual suffering from familial ALS are provided. Also provided are methods of increasing the survival time of an individual suffering from familial ALS. These methods employ antisense oligonucleotides targeted to SOD1, for use in inhibiting the expression of SOD1 in the central nervous system of an individual suffering from familial ALS.

Abstract: A vehicular powertrain has output torque established in accordance with various torque contributions in including throttle and brake torques. Throttle torque contribution is reduced proportionally to the amount of brake torque requested. Furthermore, such torque reductions are less aggressively applied with increasing throttle torques requested.

Abstract: A method for providing an active engine stop of the engine of a hybrid electric vehicle. The method utilizes the electric machine to oppose and rapidly stop the rotation of the engine at a controlled rate. The method includes the calculation of an input speed reduction trajectory using the engine speed when the active engine stop request is made and a predetermined speed reduction interval. The speed reduction interval is less than a time from the active stop request to the shutoff command to the electric machine The method provides rapid deceleration of the engine, particularly through the powertrain resonance speed, reducing the amount of vibration energy dissipated through the powertrain and chassis. The method removes the electric machine torques from the engine prior to achieving zero engine speed in order to avoid imparting a negative engine speed or counter-rotation of the engine.

Abstract: Network apparatuses, networks, computer program products, and management station operational methods are provided. One aspect of the invention provides a network apparatus including a management station adapted to couple with a network including a plurality of managed devices, the management station being configured to output a plurality of initial commands for application to respective managed devices, the initial commands being configured to stimulate initial responses from the managed devices, the management station being further configured to receive the initial responses, to identify responding ones of the managed devices responsive to the received initial responses, and to provide an asset table containing the identified managed devices.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.

Abstract: Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus or phospholipase A2 or to modulate the telomere length of a chromosome are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases and diseases associated with elevated levels of phospholipase A2 are also provided. Methods of modulating telomere length of a chromosome are also provided; modulation of telomere length is believed to play a role in the aging process of a cell and in control of malignant cell growth.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.